GeneDx Holdings Corp. WGS

About GeneDx Holdings Corp. (WGS): stock profile, AI score and financials

GeneDx Holdings Corp. (WGS) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores WGS at 35.6/100 on a composite quality score built from its SEC filings, placing it at rank #2,289 of 2,925 stocks — the bottom half of the AI-ranked universe. WGS scores in the top quartile across revenue growth (90.7). Areas of concern include balance sheet strength (10.1) and profitability (14.0), which score below median versus the broader universe. Shareholder dilution risk is elevated at 19.1/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), GeneDx Holdings Corp. reports quarterly revenue of $114.4M, net income of $-17.7M, an operating margin of -15.3%. Top institutional holders of WGS by reported 13-F value include Corvex Management, Casdin Capital, BlackRock, based on the most recent SEC filings. WGS trades on the Nasdaq exchange and files with the SEC under CIK 1818331. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate WGS daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for GeneDx Holdings Corp. directly from SEC EDGAR.

Financials through the period ended Jun 30, 2026SEC EDGAR: CIK 1818331 →